Nephrol Dial Transplant (1995) 10: 2228-2234
© 1995 European Renal Association-European Dialysis and Transplant Association
research-article
Low-dose calcitriol prevents the rise in 1,84 iPTH without affecting serum calcium and phosphate in patients with moderate renal failure (prospective placebo-controlled multicentre trial)
1Departments of Internal Medicine: Heidelberg Jena, Hannover, Greifswald and Würzburg, Germany
BACKGROUND: Higher doses of calcitriol are effective in lowering markedly elevated 1,84 PTH levels of patients with renal secondary hyperparathyroidism. It has not been established, however, whether prophylactic administration of low doses of calcitriol prevents an increase of 1,84 PTH without causing side-effects, i.e. hypercalcaemia, hypercalciuria, or hyper-phosphataemia.
STUDY DESIGN: We carried out a placebo-controlled, double-blind prospective multicentre trial over 12 months in 45 patients with mild to moderate renal failure. Criteria for inclusion were S-creatinine 1.4mg/dl and 1,84 PTH>6pmol/l (normal 6). Calcitriol 0.125 ug/day per os was compared with placebo. The patients received calcium carbonate per os if serum P exceeded 1.7 mmol/1.
RESULTS: Baseline 1,84 iPTH concentrations were not significantly different, i.e. 14.0 pmol/1 (6.7–63.3) on placebo vs 16.2 (6.85–82.0) on calcitriol. Intention to treat analysis revealed a significant difference of final 1,84 iPTH, i.e. 27.8 (4.2–68.5) on placebo vs 18.2 (4.45–75.5) on calcitriol. On post-hoc analysis the difference was even more pronounced at S-creatinine concentrations above 3 mg/dl. S-calcium, S-phosphate, and urinary excretion of calcium did not change significantly on either placebo or on calcitriol. There were no episodes of hypercalcaemia or hyperphosphataemia. There was no significant difference of final S-creatinine or change in S-creatinine between placebo and calcitriol. One patient on calcitriol and two on placebo progressed to terminal renal failure. Bone alkaline phosphatase as a non-invasive index of bone metabolism was not decreased to subnormal levels.
CONCLUSIONS: The results document that a therapeutic window exists in patients with moderate renal failure and elevated of 1,84 iPTH, where low-dose calcitriol (0.125 ug/day) prevents the increase in 1,84 iPTH without causing side-effects. This observation suggests that the parathyroid is more sensitive to calcitriol than intestine and bone.
Keywords: low-dose calcitriol; 1,84 iPTH; moderate renal failure; side-effects; parathyroid; multicentre trial
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  W. Al-Badr and K. J. Martin Vitamin D and Kidney Disease Clin. J. Am. Soc. Nephrol., September 1, 2008; 3(5): 1555 - 1560. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. B. Shoben, K. D. Rudser, I. H. de Boer, B. Young, and B. Kestenbaum Association of Oral Calcitriol with Improved Survival in Nondialyzed CKD J. Am. Soc. Nephrol., August 1, 2008; 19(8): 1613 - 1619. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. P. Kovesdy, S. Ahmadzadeh, J. E. Anderson, and K. Kalantar-Zadeh Association of Activated Vitamin D Treatment and Mortality in Chronic Kidney Disease Arch Intern Med, February 25, 2008; 168(4): 397 - 403. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Palmer, D. O. McGregor, P. Macaskill, J. C. Craig, G. J. Elder, and G. F.M. Strippoli Meta-analysis: Vitamin D Compounds in Chronic Kidney Disease Ann Intern Med, December 18, 2007; 147(12): 840 - 853. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Martin and E. A. Gonzalez Metabolic Bone Disease in Chronic Kidney Disease J. Am. Soc. Nephrol., March 1, 2007; 18(3): 875 - 885. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Tian, Y. Liu, L. A. Williams, and D. de Zeeuw Potential role of active vitamin D in retarding the progression of chronic kidney disease Nephrol. Dial. Transplant., February 1, 2007; 22(2): 321 - 328. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rodriguez, E. Nemeth, and D. Martin The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism Am J Physiol Renal Physiol, February 1, 2005; 288(2): F253 - F264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Jehle Steroid-induced osteoporosis: how can it be avoided? Nephrol. Dial. Transplant., May 1, 2003; 18(5): 861 - 864. [Full Text] [PDF]
|
|
|
|
|
|
A. Jara, S. Gonzalez, A. J. Felsenfeld, C. Chacon, A. Valdivieso, R. Jalil, and B. Chuaqui Failure of high doses of calcitriol and hypercalcaemia to induce apoptosis in hyperplastic parathyroid glands of azotaemic rats Nephrol. Dial. Transplant., March 1, 2001; 16(3): 506 - 512. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Clase, G. L. Norman, M. L. Beecroft, and D. N. Churchill Albumin-corrected calcium and ionized calcium in stable haemodialysis patients Nephrol. Dial. Transplant., November 1, 2000; 15(11): 1841 - 1846. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. CANALEJO, Y. ALMADÉN, V. TORREGROSA, J. C. GOMEZ-VILLAMANDOS, B. RAMOS, J. M. CAMPISTOL, A. J. FELSENFELD, and M. RODRÍGUEZ The In Vitro Effect of Calcitriol on Parathyroid Cell Proliferation and Apoptosis J. Am. Soc. Nephrol., October 1, 2000; 11(10): 1865 - 1872. [Abstract] [Full Text]
|
|